These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2007-005854-21 A multicenter Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concenpt trial to determine the antiviral activity, pharmacokinetics, tolerability and safety of RDEA806 in HIV-1 positiv... 2008-06-23 due-trials
Ongoing 2008-002315-41 Estudio de dosis variables, controlado con placebo, multicéntrico, doble ciego y aleatorio para evaluar la eficacia y seguridad del RDEA806 en pacientes hiperuricémicos con gota sintomática Randomize... not-yet-due
Not reported Terminated 2008-005113-21 A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected, A... 2009-08-07 due-trials
Reported results 2009-013055-30 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients with Gout 2012-08-10 due-trials
Reported results 2009-014660-19 Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Combinación, para Evaluar la Seguridad, Eficacia y la Posible Interacción Farmacocinética de RDEA594 y Alopurinol en Pacien... 2016-09-02 due-trials
Completed, but no date, and reported results 2009-014762-26 A Phase 2, Multiple-Dose, Pharmacokinetic and Pharmacodynamic Study of RDEA594 in Gout Patients with Hyperuricemia and Gout with Renal Insufficiency bad-data
Reported results 2011-002453-65 Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) 2013-01-07 due-trials
Reported results 2011-003756-39 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or Co... 2013-10-23 due-trials
Reported results 2011-003767-29 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with ... 2014-05-14 due-trials
Reported results 2011-003768-55 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum U... 2014-04-17 due-trials
Reported results 2012-002956-18 A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects with Gout 2014-06-20 due-trials
Reported results 2012-004389-16 A Long-Term Extension Study of Lesinurad in Combination with Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol 2016-11-17 due-trials

Related organisations

Over time organisations can merge, or split.

We think Ardea Biosciences Inc. is now effectively part of Astrazeneca.